Tissue Physiology of Cynomolgus Monkeys: Cross-Species Comparison and Implications for Translational Pharmacology

Abstract

We previously performed a comparative assessment of tissue-level vascular physiological parameters in mice and rats, two of the most commonly utilized species in translational drug development. The present work extends this effort to non-human primates by measuring tissue-and organ-level vascular volumes (V v), interstitial volumes (V i), and blood flow rates (Q) in cynomolgus monkeys. These measurements were accomplished by red blood cell labeling, extracellular marker infusion, and rubidium chloride bolus distribution, respectively, the same methods used in previous rodent measurements. In addition, whole-body blood volumes (BV) were determined across species. The results demonstrate that V v , V i , and Q, measured using our methods scale approximately by body weight across mouse, rat, and monkey in the tissues considered here, where allometric analysis allowed extrapolation to human parameters. Significant differences were observed between the values determined in this study and those reported in the literature, including V v in muscle, brain, and skin and Q in muscle, adipose, heart, thymus, and spleen. The impact of these differences for selected tissues was evaluated via sensitivity analysis using a physiologically based pharmacokinetic model. The blood-brain barrier in monkeys was shown to be more impervious to an infused radioactive tracer, indium-111-pentetate, than in mice or rats. The body weight-normalized total BV measured in monkey agreed well with previously measured value in rats but was lower than that in mice. These findings have important implications for the common practice of scaling physiological parameters from rodents to primates in translational pharmacology.

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19

“…4). These concentrations were calculated using non-interstitial volumes of 0.75 and 0.9 mL/g lung and liver, respectively, and an assumed volume of 0.83 mL/g kidney (13). In contrast to lung and kidney, for which 48 h concentrations could be reasonably estimated by extrapolation below the assay calibration curves for all but one of the three kidney samples, no peak corresponding to AT-9010 was detected in any of the liver samples at the 48-h post dose time point.…”

Whole-Body Pharmacokinetics of Antibody in Mice Determined using Enzyme-Linked Immunosorbent Assay and Derivation of Tissue Interstitial Concentrations

“…22 Similarly, free label that does not bind to red blood cell causes bias to the residual blood volume measurement. 23 Thus, use of labelled markers may not help in accurately accounting for blood contamination in tissues.…”

Monitoring tumor cell death in murine tumor models using deuterium magnetic resonance spectroscopy and spectroscopic imaging

“…Labeled fumarate in the liver and heart muscle can be explained, at least in part, by labeled fumarate present in the blood pool. With a blood [2,3-2 H 2 ]fumarate concentration of 12 mM at 20 min after injection (Table 2), and using blood volumes in mouse liver and kidney of ∼0.2 mL/g tissue (31), and accessible volumes (vascular plus interstitial) in liver and heart muscle ∼0.2 mL/g (32) gives a calculated concentration of labeled fumarate in the liver, kidney, and heart muscle blood pools of ∼2.4 μmols/g tissue. This is similar to the measured tissue concentration of 2.1 μmols/g in liver, although above that measured in the heart, which was 1.2 μmols/g.…”